Clinical Studies

Immune-mediated thrombocytopenia (ITP) is a disorder characterized by severely low platelets due to attack by white blood cells. This is often associated with bruising and occasionally severe bleeding episodes.

Verdinexor is a chemotherapy drug that has been conditionally approved by the FDA for the treatment of canine lymphoma. Verdinexor is a selective inhibitor of nuclear export (SINE) compound, and this family of drug has demonstrated encouraging results in preclinical studies when combined with other chemotherapeutic drugs.

The intestinal microbiota are highly functional, with a combined genome (termed the microbiome) that is approximately 130-160 times larger than the human or canine genome. The microbiome is a highly functional organ and produces approximately 1,000 different metabolites, many of which have systemic effects in the dog.

Following removal of the primary tumor and adjuvant chemotherapy, the development of lung metastasis is the most common cause of mortality in dogs with osteosarcoma. A distinctive feature of lung metastases of osteosarcoma in human patients is the surprising benefit that can result from surgical resection of the lung nodules. The use of surgery to

Naturally occurring cancers in dogs have been as used as models for human cancers for many reasons; however, the genomic profiles of many of these cancers are still incompletely understood. Further definition of these genomic landscapes will allow for improved development of novel diagnostics and therapeutics to diagnose and treat these cancers. The objective of this

Research Type Ethos Discovery De Novo Study Description Paclitaxel is a human chemotherapeutic that has demonstrated a broad spectrum of activity against  several human and canine cancers. Previous formulations of paclitaxel have been poorly absorbed in dogs, limiting its therapeutic value. Oraxol is a novel oral formulation of paclitaxel that is combined with a second

Ethos Discovery now seeks to deliver a highly advanced clinical trial program investigating the use of novel drugs for the treatment of Hemangiosarcoma (HSA) with the goal of curing this aggressive cancer. This study will ask if drugs specifically matched to the genomic subtypes of patients with HSA will result in improved outcomes.

A new cat diet has been shown to reduce body fat while maintaining lean muscle mass in cats. Accordingly, the following clinical study now seeks to determine if feeding this new diet without concurrent insulin therapy can induce insulin remission in cats with diabetes.

This clinical study seeks to determine if feeding the new diet in combination with insulin can improve glycemic control in dogs with moderately controlled diabetes.

This study will compare certain markers in the blood that are specific to cancer, but not found in healthy dogs, before and after surgical biopsy or surgical removal of a mass.

This study will compare markers in the blood that are specific to cancer but not found in healthy dogs, before and after treatment for cancer has begun.

Intestinal dysbiosis has been associated with tumor progression of colorectal, lung, and breast cancer in human patients. The objective of this study is to determine whether or not canine patients diagnosed with osteosarcoma have intestinal dysbiosis and if the presence of intestinal dysbiosis is associated with metastasis in these patients.